AR127625A1 - Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos - Google Patents

Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos

Info

Publication number
AR127625A1
AR127625A1 ARP220103080A ARP220103080A AR127625A1 AR 127625 A1 AR127625 A1 AR 127625A1 AR P220103080 A ARP220103080 A AR P220103080A AR P220103080 A ARP220103080 A AR P220103080A AR 127625 A1 AR127625 A1 AR 127625A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
independently selected
alkoxy
halogen
Prior art date
Application number
ARP220103080A
Other languages
English (en)
Spanish (es)
Inventor
John Buell
Frederick Cohen
Ryan Pemberton
Hunter P Shunatona
Lan Wang
Mark Edward Zak
Original Assignee
Nurix Therapeutics Inc
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc, Gilead Sciences Inc filed Critical Nurix Therapeutics Inc
Publication of AR127625A1 publication Critical patent/AR127625A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
ARP220103080A 2021-11-10 2022-11-09 Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos AR127625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10

Publications (1)

Publication Number Publication Date
AR127625A1 true AR127625A1 (es) 2024-02-14

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103080A AR127625A1 (es) 2021-11-10 2022-11-09 Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos

Country Status (12)

Country Link
US (2) US12091426B2 (cg-RX-API-DMAC7.html)
EP (1) EP4430052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543377A (cg-RX-API-DMAC7.html)
KR (1) KR20240101654A (cg-RX-API-DMAC7.html)
CN (1) CN118510786A (cg-RX-API-DMAC7.html)
AR (1) AR127625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022388571A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235913A1 (cg-RX-API-DMAC7.html)
IL (1) IL312361A (cg-RX-API-DMAC7.html)
MX (1) MX2024005431A (cg-RX-API-DMAC7.html)
TW (1) TW202334170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
EP3873608A1 (en) * 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN114423463B (zh) * 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
TWI918648B (zh) * 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途

Also Published As

Publication number Publication date
US20240018162A1 (en) 2024-01-18
IL312361A (en) 2024-06-01
WO2023086399A1 (en) 2023-05-19
US20240400587A1 (en) 2024-12-05
KR20240101654A (ko) 2024-07-02
MX2024005431A (es) 2024-07-19
JP2024543377A (ja) 2024-11-21
CA3235913A1 (en) 2023-05-19
EP4430052A1 (en) 2024-09-18
AU2022388571A1 (en) 2024-05-09
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
CN118510786A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR115092A1 (es) Inhibidores de magl
AR114998A1 (es) Compuestos de benzamida
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR114417A1 (es) Compuestos y métodos de uso
AR110922A1 (es) Compuestos inhibidores del vih
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR104789A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
AR116315A1 (es) Compuestos de triazolo-pirimidina y usos de los mismos
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR118119A1 (es) Compuestos de pirido-pirimidinilo y métodos de uso
AR093581A1 (es) Antibioticos macrociclicos de amplio espectro
AR115936A1 (es) Compuestos útiles en terapia del vih
AR116400A1 (es) Compuesto de imidazopiridinona
AR116905A1 (es) Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor
AR121674A1 (es) Amidas heterocíclicas como inhibidoras del receptor de tirosina quinasa de tipo iii
AR108778A1 (es) Compuestos antibacterianos
AR126442A1 (es) Inhibidores de map4k1
AR123241A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos
AR108327A1 (es) Compuestos pirimidinona fusionados sustituidos